Why Canopy Growth Withdraws Penelope, a Sustainable Medical Cannabis Strain

Canopy Growth Polska, one of the leading suppliers of medical cannabis on the Polish market, has announced the decision to withdraw one of the most recognizable varieties of medical cannabis– Canopy Growth THC 8%, CBD 7% (PENELOPE).

The context of the withdrawal of the Penelope variety

Canopy Growth Polska, part of the international Canopy Growth Corporation, has been providing Polish patients with high-quality medical products based on hemp for years. The company is a market leader, and its products are appreciated by both patients and doctors. The Penelope strain, characterized by a balanced content of the cannabinoids THC (8%) and CBD (7%), was one of the company’s flagship products, offering patients a unique combination of ingredients with therapeutic potential.

Penelope gained popularity thanks to its balanced cannabinoid profile, which is rare on the Polish market. The balanced content of THC and CBD made this strain preferred by many patients who needed support in treating various ailments, such as chronic pain, inflammation, as well as sleep problems or anxiety.

Reasons for Penelope’s withdrawal

The decision to discontinue Penelope was difficult but necessary for Canopy Growth Polska. The main reason for this decision is the aging of the strain, which has made it more susceptible to quality fluctuations. Over time, the genetics of the plant can weaken, which consequently leads to a decrease in the stability of the product. For a company whose priority is to provide the highest quality products, this was an unacceptable risk.

Canopy Growth Polska emphasizes that concern for quality and patient safety has always been and remains the top priority. The Penelope recall aims to prevent situations in which the quality of the product could no longer meet the high standards to which Polish patients and healthcare workers have become accustomed.

“The decision to discontinue Penelope was very difficult for us, as it is a strain that enjoyed huge interest. However, our commitment to providing only the highest quality products forced us to take this step,” says a representative of Canopy Growth Polska.

Canopy Growth Polska’s response and plans

Although the withdrawal of Penelope may be disappointing for many patients, Canopy Growth Polska does not leave them without support. Intensive work is already underway to introduce a replacement that will be characterized by a similar, balanced THC/CBD profile. The new variety that the company is working on is to not only meet, but even exceed the expectations of patients in terms of quality and effectiveness.

The company also announced the introduction of other medical strains that have a similar profile to Penelope. These products are expected to be available soon, allowing patients who have relied on the balanced effects of THC and CBD to continue their therapy.

“The process of registering new varieties of medical cannabis in Poland is time-consuming, but we are constantly working to provide patients with appropriate substitutes as quickly as possible. Our goal is to ensure continuity of therapy and support for doctors and patients,” adds the company representative.

The significance of the decision for the medical marijuana market in Poland
The withdrawal of Penelope from the market is a significant event for medical marijuana patients in Poland. This strain, due to its unique properties, was often the first choice for people starting cannabis therapy. Now they will have to look for alternatives, which can be a challenge, especially in the context of the lack of products with a similar profile on the market.

This decision may also affect the dynamics of the medical marijuana market in Poland. Other producers may start introducing strains with a similar composition to the market to meet the demand for products similar to Penelope. On the other hand, Canopy Growth Polska, through its announcements, is trying to maintain its leadership position by preparing new strains that are supposed to meet the needs of patients.

Summary

The withdrawal of Penelope by Canopy Growth Polska is a decision dictated by the responsibility for quality and patient safety. Although it may be difficult for patients to accept, it is also proof that the company prioritizes its obligations to the market and consumers. We can expect that new products will soon appear on the market that will not only fill the gap after Penelope, but also raise the standards in cannabis therapy in Poland.

Canopy Growth Polska remains committed to monitoring the quality of its products and working with physicians and pharmacists to ensure the continuity of effective and safe therapies. Patients can be assured that the company will continue to take appropriate steps to meet their expectations and provide the highest quality medical products.

__

(Featured image by CRYSTALWEED cannabis via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in FaktyKonopne. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us